#United States #Washington #Alzheimer's #Advocacy #ApoE4

ApoE4.Info and ApoE4 Alzheimer's Alliance Unite for Advocacy

On March 16, 2026, ApoE4.Info, Inc. and the ApoE4 Alzheimer's Alliance (A3) announced their strategic partnership aimed at enhancing research, education, and public policy regarding individuals who are carriers of the ε4 allele of the APOE gene, which is the most significant genetic risk factor for late-onset Alzheimer's disease. This alliance has emerged to address a critical gap—APOE4 carriers account for up to 65% of Alzheimer's diagnoses, yet their unique biological characteristics are often overlooked in clinical practices and research methodologies.

As Julie Gregory, President of ApoE4.Info, poignantly stated, "APOE4 carriers are not a small subgroup—we are the majority of patients." The partnership signals a call to action to redefine how the medical community approaches Alzheimer’s research and treatment protocols. For too long, the typical research framework has grouped APOE4 carriers with non-carriers, failing to consider the distinct biological processes present within this large population.

William Burke, Executive Director of the ApoE4 Alzheimer's Alliance, emphasized the need for change, suggesting that the current policies and research infrastructures have treated a significant segment of the Alzheimer’s community as a marginal group rather than recognizing their majority status. The combined efforts of ApoE4.Info and A3 aim to ensure that the specific genetic and metabolic realities of the APOE4 population are taken into account in public policy and research agendas.

This partnership is focused not only on raising awareness but also on pushing for comprehensive advocacy tailored precisely to the needs of APOE4 carriers. A fundamental goal is to integrate routine APOE stratification into clinical trials, promoting research that values genotype-specific prevention and treatment strategies. Moreover, both organizations aspire to represent the voices of carriers and their families more prominently, ensuring that their lived experiences inform future Alzheimer's care.

The collaboration will serve as a vital platform, merging ApoE4.Info’s rich network of education and community support with the focused advocacy efforts of the ApoE4 Alzheimer's Alliance. They invite clinicians, researchers, industry leaders, and policymakers to participate in this urgent call for change, cultivating a path that honors rigorous scientific inquiry while developing equitable healthcare solutions.

About ApoE4.Info

Founded in 2013, ApoE4.Info is a nonprofit organization dedicated to empowering APOE4 carriers through education and community support. It provides evidence-based resources aimed at helping individuals navigate their unique genetic risks associated with Alzheimer’s, from early detection to informed engagement in ongoing research.

About ApoE4 Alzheimer's Alliance (A3)

The ApoE4 Alzheimer’s Alliance is an advocacy organization focused on impacting public policy and research priorities that address the needs of APOE4 carriers. With a commitment to ensuring that this significant population is adequately represented within federal research agendas, they work diligently to promote genotype-driven strategies in addressing Alzheimer’s disease.

Through this partnership, ApoE4.Info and the ApoE4 Alzheimer's Alliance are creating a future where Alzheimer's care is optimized to meet the distinctive needs of today's carriers, acknowledging their majority status and the importance of tailored medical solutions in combating the disease.